التفاصيل البيبلوغرافية
| العنوان: |
Rapid generation of NY-ESO-1-specific CD4 T HELPER 1 cells for adoptive T-cell therapy. |
| المؤلفون: |
Kayser, Simone, Boβ, Cristina, Feucht, Judith, Witte, Kai-Erik, Scheu, Alexander, Bülow, Hans-Jörg, Joachim, Stefanie, Stevanović, Stefan, Schumm, Michael, Rittig, Susanne M, Lang, Peter, Röcken, Martin, Handgretinger, Rupert, Feuchtinger, Tobias |
| المصدر: |
OncoImmunology; May2015, Vol. 4 Issue 5, p0-0, 0p |
| مصطلحات موضوعية: |
T helper cells, T cells, CD4 antigen, IMMUNE system, INTERLEUKIN-2, IMMUNOTHERAPY, THERAPEUTICS |
| مستخلص: |
Tumor-associated antigens such as NY-ESO-1 are expressed in a variety of solid tumors but absent in mature healthy tissues with the exception of germline cells. The immune system anti-cancer attack is mediated by cell lysis or induction of growth arrest through paralysis of tumor cells, the latter of which can be achieved by tumor-specific CD4+, IFNγ-producing THelpertype 1 (TH1) cells. Translation of these immune-mediated mechanisms into clinical application has been limited by availability of immune effectors, as well as the need for complexin vitroprotocols and regulatory hurdles. Here, we report a procedure to generate cancer-testis antigen NY-ESO-1-targeting CD4+TH1 cellsin vitrofor cancer immunotherapy in the clinic. After in vitro sensitization by stimulating T cells with protein-spanning, overlapping peptide pools of NY-ESO-1 in combination with IL-7 and low dose IL-2, antigen-specific T cells were isolated using IFNγ capture technique and subsequently expanded with IL-2, IL-7 and IL-15. Large numbers of NY-ESO-1-specific CD4+T cells with a TH1 cytokine profile and lower numbers of cytokine-secreting CD8+T cells could be generated from healthy donors with a high specificity and expansion potential. Manufactured CD4+T cells showed strong specific TH1-responses with IFNγ+, TNFα+, IL-2+and induced cell cycle arrest and apoptosis in tumor cells. The protocol is GMP-grade and approved by the regulatory authorities. The tumor-antigen specific CD4+TH1 lymphocytes can be adoptively transferred as a T-cell therapy to boost anticancer immunity and this novel cancer treatment approach is applicable to both T cells from healthy allogeneic donors as well as to autologous T cells derived from cancer patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of OncoImmunology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder